<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05002738</url>
  </required_header>
  <id_info>
    <org_study_id>21-3936</org_study_id>
    <nct_id>NCT05002738</nct_id>
  </id_info>
  <brief_title>Desogestrel-containing COCP Pharmacokinetic Validation Study</brief_title>
  <official_title>Validation of 24-hour Trough Concentration as a Surrogate for Intensive Pharmacokinetic Measurements for a Combined Oral Contraceptive Pill Containing Desogestrel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to validate prior pharmacokinetic research with combined oral contraceptive&#xD;
      pill users that supports utilizing a 24-hour trough concentration as an accurate proxy for&#xD;
      the intensive pharmacokinetic parameter of area under the curve (gold standard&#xD;
      pharmacokinetics). The original pharmacokinetic studies were performed with a&#xD;
      levonorgestrel-containing oral contraceptive pill and we aim to duplicate those findings with&#xD;
      a desogestrel-containing oral contraceptive pill.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrolled participants will be started on a standard pack of desogestrel-containing oral&#xD;
      contraceptive pills and undergo an intensive pharmacokinetic study visit on day 21 of the&#xD;
      pill pack. This will entail 11 serial blood draws and a final blood draw the next day at 24&#xD;
      hours post-pill intake to measure and calculate a pharmacokinetic area under the curve for&#xD;
      both the estrogen and progestin components of the pill. We will then correlate the 24-hour&#xD;
      trough measurement to the area under the curve measures to determine the correlation of these&#xD;
      measurements.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum etonogestrel concentrations</measure>
    <time_frame>24 hours</time_frame>
    <description>12 serum measurements taken over the course of 24 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum ethinyl estradiol concentrations</measure>
    <time_frame>24 hours</time_frame>
    <description>12 serum measurements taken over the course of 24 hours</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Overall Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined oral contraceptive pill containing 0.15mg desogestrel and 0.03mg ethinyl estradiol for 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desogestrel and Ethinyl Estradiol Tablets</intervention_name>
    <description>Combined oral contraceptive pill</description>
    <arm_group_label>Overall Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy females aged 18-45 years&#xD;
&#xD;
          -  Body-mass index â‰¥18.5kg/m2&#xD;
&#xD;
          -  Willing to abstain from medications and supplements known to induce/inhibit CYP3A4&#xD;
             during the study&#xD;
&#xD;
          -  Normal blood pressure measurement at screening (systolic &lt;140mmHg, diastolic &lt;90mmHg)&#xD;
&#xD;
          -  Negative urine pregnancy test at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently taking any known CYP3A4 inducers/inhibitors&#xD;
&#xD;
          -  Medical conditions that affect liver function (e.g. hepatitis, cirrhosis)&#xD;
&#xD;
          -  Any contraindications to estrogen-containing contraception (based on any category 3 or&#xD;
             4 recommendations from the CDC MEC guidelines)&#xD;
&#xD;
          -  Use of an injectable contraceptive method within the last 6 months or current use of&#xD;
             an ENG contraceptive implant&#xD;
&#xD;
          -  Childbirth within the last 6 months&#xD;
&#xD;
          -  Known allergy or insensitivity to combined oral contraceptive pills&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Dindinger</last_name>
      <phone>303-724-8482</phone>
      <email>eva.dindinger@cuanschutz.edu</email>
    </contact>
    <contact_backup>
      <last_name>Morgan Pena</last_name>
      <email>morgan.pena@cuanschutz.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Aaron Lazorwitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 4, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Desogestrel</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

